As venture capital continues flowing heavily toward artificial intelligence startups, many traditional SaaS companies are facing growing pressure to prove long-term relevance in a rapidly changing technology landscape.
But healthcare data platform H1 is making the case that not all software businesses are equally vulnerable to disruption.
The New York-based company has secured $40 million in new funding led by CVS Health Ventures, the investment arm of healthcare giant CVS Health, highlighting continued investor confidence in data-driven healthcare infrastructure platforms.
The investment comes despite a broader slowdown in funding for mature SaaS companies, particularly those founded before the recent generative AI boom.
Why H1 Believes Its Business Is Different
Founded nine years ago, H1 specializes in collecting and organizing detailed healthcare and physician data used by pharmaceutical companies, health insurers, hospitals, and healthcare organizations.
Its platform helps enterprise healthcare customers identify physicians, analyze medical expertise, support clinical trial recruitment, and improve healthcare engagement strategies.
According to H1 co-founder and CEO Ariel Katz, the company’s value lies less in workflow automation and more in the proprietary healthcare data infrastructure it has built over time.
Katz argued that while generative AI models can increasingly replicate many software workflows, highly specialized and deeply structured healthcare datasets remain significantly harder to reproduce.
Rather than viewing AI companies as competitors, H1 sees potential opportunities to become an important data provider to the growing AI ecosystem.
CVS Health Ventures Signals Strategic Confidence
The funding round was led by CVS Health Ventures, reinforcing growing interest among large healthcare enterprises in owning or partnering with infrastructure providers that manage critical healthcare intelligence and data systems.
Katz noted that H1 was not actively seeking new capital.
The company became cash flow and EBITDA profitable last year and expects revenue growth of more than 40% this year.
However, partnering with one of the largest healthcare organizations in the world presented a strategic opportunity difficult to ignore.
The deal also reflects how corporate venture capital firms are increasingly prioritizing investments tied directly to operational healthcare infrastructure, data modernization, and AI-enabled healthcare services.
Healthcare Data Remains a Valuable Enterprise Asset
H1 operates at the intersection of healthcare data, enterprise software, and AI-driven analytics — an area many investors continue viewing as resilient despite broader changes in the software market.
Healthcare organizations are under increasing pressure to improve operational efficiency, optimize clinical engagement, and modernize how medical information is managed and distributed.
Structured healthcare datasets have become especially important as AI models increasingly require high-quality domain-specific data for training, validation, and enterprise deployment.
That dynamic may help companies like H1 remain strategically important even as many traditional SaaS categories face intensified competition from AI-native platforms.
Growth Through Profitability and Consolidation
Like many companies that raised funding during the peak of the 2021 venture capital cycle, H1 has shifted focus toward profitability and operational discipline following the broader market correction.
The company was previously valued at approximately $750 million during a 2021 funding round led by Altimeter Capital.
Since then, H1 has focused on expanding its platform through acquisitions of smaller competitors and complementary healthcare data businesses while strengthening its financial position.
Its ability to remain profitable while still growing places it in a relatively small group of enterprise software companies successfully navigating the post-2022 venture capital environment.
Enterprise Healthcare Platforms Continue Evolving
The investment also reflects a larger trend across healthcare technology.
As healthcare systems increasingly adopt AI tools, digital infrastructure, and advanced analytics platforms, the value of reliable healthcare data continues to grow.
Companies operating in highly regulated industries such as healthcare may face a different competitive environment compared to general SaaS businesses because proprietary datasets, compliance expertise, and industry-specific integrations create stronger barriers to entry.
For H1, the new funding provides additional resources to continue expanding its healthcare intelligence platform while strengthening relationships across the pharmaceutical, insurance, and provider ecosystem.